Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 2/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843090 | 0.78 | HTR1A (0.42) | ALDH1A1SMN1; SMN2HTR1ADRD2HTR2A | |
| SCHEMBL14531016 | 0.75 | ALDH1A1 (0.58) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL20305613 | 0.75 | LMNA (0.50) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL27626936 | 0.75 | LMNA (0.50) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL28244845 | 0.73 | PDPK1 (0.61) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL201830 | 0.73 | ALDH1A1 (0.61) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL11638058 | 0.73 | LMNA (0.61) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL14531430 | 0.73 | ALDH1A1 (0.56) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL14532121 | 0.73 | ALDH1A1 (0.56) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL410846 | 0.72 | HTR1A (0.64) | ALDH1A1PDPK1SMN1; SMN2LMNAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018081276-A1 | COMPOUNDS | TESARO, INC. (US) | 2018-05-03 | — | — | WO | claimed |
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152700-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | ALDH1A1 623/4885PDPK1 1431/4885SMN1; SMN2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.